UroGen Pharma Ltd. (URGN) — Stock Score Summary

UroGen Pharma Ltd. (URGN) has a MoatMap StockRank of 70/100 based on Quality (33/100), Value (48/100), and Momentum (73/100) factor scores. The current signal is BUY. UroGen Pharma is a specialized biotech with low quality scores and high cash burn. It does not possess the established moat or cash flow profile required for our portfolio.

UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for urological cancers. The company's competitive moat is its proprietary RTGel technology, a sustained-release hydrogel that overcomes the bladder's natural clearance mechanisms to deliver localized treatment. It operates as a specialized niche player in the uro-oncology market.

Key Financial Metrics

Price$28.18
Market Cap$1.4B
P/E (Forward)22.46
Price/Book-10.82
Return on Invested Capital-89.6%
Gross Margin89.9%
Operating Margin-39.8%
Revenue Growth151.6%
Free Cash Flow$-109M

UroGen Pharma Ltd. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is UroGen Pharma Ltd.’s (URGN) StockRank?
MoatMap’s StockRank for UroGen Pharma Ltd. (URGN) is 70/100, with a Buy signal. It is a composite of Quality (33), Value (48), and Momentum (73) factor ranks across MoatMap’s 19,000+ stock universe.
Does UroGen Pharma Ltd. have an economic moat?
UroGen Pharma Ltd. (URGN) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is UroGen Pharma Ltd. a buy, hold, or sell?
MoatMap’s current signal for UroGen Pharma Ltd. (URGN) is Buy, based on a StockRank of 70/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is UroGen Pharma Ltd. in?
UroGen Pharma Ltd. (URGN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksURGN deep dive reportAI ChampionsHow we score stocksSense-check another stock